Improving Evidence-Based Primary Care for Chronic Kidney Disease

Sponsor
American Academy of Family Physicians (Other)
Overall Status
Completed
CT.gov ID
NCT01767883
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH), University at Buffalo (Other), University of Colorado, Denver (Other), National Kidney Foundation (Other)
27,000
1
2
55
490.9

Study Details

Study Description

Brief Summary

Background: Chronic Kidney Disease (CKD) is under-recognized and under-treated in primary care offices and primary care physicians are generally not familiar with treatment guidelines. Even when diagnosed properly, as a chronic condition CKD is frequently associated with co-morbidities that make effective treatment difficult due to complexity of care. Availability of Clinical Decision Support (CDS) for CKD may help promote effective, evidence-based care, but evidence suggests that CDS alone may not be sufficient for quality improvement and other interventions such as CDS plus practice facilitation may be needed.

Purpose: The project aims to: 1) assess the viability of CDS in implementing evidence-based guidelines for Primary Care Practices (PCPs) and 2) to develop evidence-based practice guidelines that PCPs may use to enhance the care they provide to a difficult to manage segment of the healthcare population.

Methods: This is a randomized controlled trial of point-of-care CDS plus full TRANSLATE model of practice change, versus CDS alone. The study aims to analyze differences in promoting evidence-based care in primary care practices. Thirty-six practices will be recruited for this study. Patient inclusion criteria: adult patients with estimated Glomerular Filtration Rate (eGFR) of <60 and >15ml/min/1.73m2 confirmed with repeat testing over three or more months. A process evaluation will be conducted between the CDS practices with facilitation and the CDS only practices to assess clinical outcomes of CKD progression and all-cause mortality. Lastly, a cost-effective analysis will compare the cost-to-benefit ratio of CDS alone to that of CDS plus TRANSLATE (i.e. practice facilitation) in relation to cost per quality adjusted years of life. This study is funded by NIH NIDDK under R01 mechanism starting on 07/01/2011 and ending on 06/30/2016.

Condition or Disease Intervention/Treatment Phase
  • Other: Facilitated Clinical Decision Support
  • Other: Clinical Decision Support Only
N/A

Detailed Description

The proposed trial tests the extent to which CDS plus facilitation promotes evidence-based care and improves the clinical outcomes of reduced disease progression and mortality in primary care practices. We also conduct an observational comparative effectiveness analysis of data from a larger database of electronic medical records in order to identify the most successful components of evidence-based care with respect to disease progression and all-cause mortality.

Specific Aim 1: Conduct a group randomized controlled trial of point-of-care computer decision support plus the full TRANSLATE model of practice change, versus computer decision support alone in promoting evidence-based care in primary care practices for all patients with an eGFR <60 and > 15 ml/min/1.73m2 confirmed with repeat testing over three or more months. (CKD stages 3 and 4) Hypothesis 1.1: CDS practices using the TRANSLATE model will provide a greater degree of evidence-based guideline-concordant care for CKD than CDS only practices.

Specific Aim 2: Conduct an intent-to-treat and process analysis between the CDS practices with facilitation versus the CDS only practices of the clinical outcomes of CKD progression and all-cause mortality.

Hypothesis 2.1: Patients with stage 3 and 4 CKD in facilitated practices will have slower CKD progression than patients in CDS only practices.

Hypothesis 2.2: Patients with stage 3 and 4 CKD in facilitated practices will have significantly lower all-cause mortality than stage 3 and 4 patients in CDS only practices.

Hypothesis 2.3: The process evaluation will determine through qualitative methods the fidelity of the facilitated TRANSLATE program; find the challenges and enablers of the implementation process, the role of facilitation, and the contextual factors that contribute to TRANSLATE decisions and strategies; and translate lessons learned into pragmatic "best practices" for future facilitation and dissemination.

Specific Aim 3: Conduct a cost-effectiveness analysis that will compare the benefit of the intervention of computer decision support alone against the intervention of computer decision support plus TRANSLATE (practice facilitation). Hypothesis 3.1 The intervention of computer decision support plus TRANSLATE is more cost-effectiveness than the intervention of computer decision support alone.

Study Design

Study Type:
Interventional
Actual Enrollment :
27000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Health Services Research
Official Title:
Improving Evidence-Based Primary Care for Chronic Kidney Disease
Actual Study Start Date :
Jul 1, 2011
Actual Primary Completion Date :
Nov 30, 2015
Actual Study Completion Date :
Jan 30, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Facilitated Clinical Decision Support

The primary care practices in this arm will receive: CKD decision support algorithms added to their Clinical Decision Support System Academic detailing concerning the rationale for the algorithms On-going mentoring and practice facilitation

Other: Facilitated Clinical Decision Support
The primary care practices in this arm will receive: CKD decision support algorithms added to their Clinical Decision Support System Academic detailing concerning the rationale for the algorithms On-going mentoring and practice facilitation Audit and feedback during quarterly reviews of practice data with the practice facilitator by videoconference.
Other Names:
  • Facilitated CDS,
  • CDS plus facilitation
  • Active Comparator: Clinical Decision Support Only

    The primary care practices in this arm will receive: CKD decision support algorithms added to their Clinical Decision Support System Academic detailing concerning the rationale for the algorithms

    Other: Clinical Decision Support Only
    CKD decision support algorithms added to their Clinical Decision Support System Academic detailing concerning the rationale for the algorithms
    Other Names:
  • CDS Only
  • "Comparator"
  • Outcome Measures

    Primary Outcome Measures

    1. Degree of evidence-based guideline-concordant care for CKD [up to 3 years]

      Percentage of patients at goal for: Control Blood Pressure Control LDL Control HbA1C Use ACE/ARB Eliminate NSAID/Cox-2 use Refer to Nephrologist Eliminate Smoking

    Secondary Outcome Measures

    1. CKD Management Process Measures [upt to 3 years]

      Percentage of patients who have: Diagnosis of CKD Annual Microalbumin/Creatinine Ratio Annual LDL Annual A1c Follow up creatinine measure Follow up ACR measure

    2. Cost of intervention [up to 3 years]

      Extra costs of the "Translate CKD" intervention and the control intervention, compared to no intervention. Claims data from Centers for Medicare & Medicaid Services, additional practice and patient costs

    3. All-cause mortality [up to 3 years]

      Death data from the CDC National Death Index

    Other Outcome Measures

    1. Process evaluation outcomes [Change from Baseline practice performance at 3 years]

      Qualitative and descriptive measure of practice performance, physician and staff satisfaction and process changes as obtained through site visit observations, interviews and questionnaires.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • all individuals whose primary care provider offices participate in the study who is over the age of 18 with a diagnosis of stages 2-4 of CKD and/or diabetes and/or hypertension and/or one eGFR <60 and/or one urine albumin/creatinine ratio >30
    Exclusion Criteria:
    • individual patients whose primary care provider's practice has not signed practice and data use agreements with the AAFP NRN to participate in this practice improvement project at the practice level

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 American Academy of Family Physicians Leawood Kansas United States 66211

    Sponsors and Collaborators

    • American Academy of Family Physicians
    • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    • University at Buffalo
    • University of Colorado, Denver
    • National Kidney Foundation

    Investigators

    • Principal Investigator: Chester H Fox, MD, State University of New York at Buffalo

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    American Academy of Family Physicians
    ClinicalTrials.gov Identifier:
    NCT01767883
    Other Study ID Numbers:
    • AAFP-CKD-102020846
    • 1R01DK090407-01A1
    First Posted:
    Jan 15, 2013
    Last Update Posted:
    Dec 12, 2018
    Last Verified:
    Dec 1, 2018

    Study Results

    No Results Posted as of Dec 12, 2018